Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson’s disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer’s disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases.
Denali Therapeutics Inc.
Unlock to Claim this listing
Add / Modify Company
3.4
Overall Excellence Rating
Industry
HealthcareCategory
Biotech & PharmaceuticalsESG/Ethical Impact
We believe we have a responsibility to the environment we live and work in. Since 1992, we have been delivering enterprise IT solutions and services, helping customers with digital transformation and complex IT challenges. While our core service has a hand in sustainability by reducing reliance on paper, shipping, and travel while making everything more efficient, we go beyond that. We’ve adopted the highest standards of environmental conservation as a core part of our business strategy and operating model.Specific Compliance Related Functions and Responsibilities: Related functions, duties, and responsibilities are defined and are connected to managing the Company’s overall environmental and sustainability compliance in all aspects. Among other members, the list below is a representation of the members and governance: Governance: Sustainability Committee. Responsible for sustainability accountability and environmental guidance and reporting. Responsible Senior Executive: Vice President, Business Management Acts as an escalation point and notifications to executive management.Recognizing the importance of financial sustainability, Denali Therapeutics Inc. integrates responsible financial practices into its strategy. Through prudent risk management, efficient resource allocation, and long-term value creation, the company aims to maintain financial stability and deliver value to its stakeholders. Denali Therapeutics Inc. places ethics at the core of its business operations. By adhering to stringent ethical codes and promoting responsible behavior throughout its supply chain, the company cultivates a culture of integrity, trust, and respect.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Awards Received
2023
Revenues
$108,000,000.00
Website Traffic
Employee Rating
3.9
Customer Rating
3.6
Company Size
100-1000
ESG Risk Rating
3